Sign InBreakout Stocks of Week 16 @ NASDAQ
NASDAQ was up last week (week 15) by 4.68% ending at 22,902.89 points after gaining 1,023.71 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are LeMaitre Vascular NASDAQ:LMAT. This stock has had a buy signal since Feb 13, 2026 when the price was $87.66 and is so far up 30.76% to $114.62. Some other companies are on our watchlist to, among these are Gladstone Land Corporation NASDAQ:LAND Paypay Corporation NASDAQ:PAYP Biogen Inc. NASDAQ:BIIB and AnaptysBio Inc NASDAQ:ANAB which all got a breakout pattern emerging.
| Date | Company | Price | Week 16 |
|---|---|---|---|
| Lemaitre Vascular | $114.62 | $114.36 | -0.227% |
| Gladstone Land Corporation | $10.39 | $10.30 | -0.87% |
| Paypay Corporation | $20.10 | $21.60 | 7.46% |
| Biogen Inc. | $172.97 | $177.35 | 2.53% |
| Anaptysbio Inc | $46.73 | $45.01 | -3.69% |
The LeMaitre Vascular stock price gained 1.69% on the last trading day (Friday, 10th Apr 2026), rising from $112.71 to $114.62. It has now gained 5 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 2.29% from a day low at $112.24 to a day high of $114.81. The price has risen in 7 of the last 10 days and is up by 3.89% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 53 thousand more shares were traded than the day before. In total, 168 thousand shares were bought and sold for approximately $19.20 million.
On May 06, 2026, it was reported that Lake Street gave LMAT a "Buy" grade with a "hold" action.
LeMaitre Vascular holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About LeMaitre Vascular:
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
The Gladstone Land Corporation stock price gained 0.678% on the last trading day (Friday, 10th Apr 2026), rising from $10.32 to $10.39. During the last trading day the stock fluctuated 1.56% from a day low at $10.27 to a day high of $10.43. The price has risen in 7 of the last 10 days and is up by 1.96% over the past 2 weeks. Volume fell on the last day by -52 thousand shares and in total, 383 thousand shares were bought and sold for approximately $3.98 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
On Nov 11, 2025, it was reported that Alliance Global Partners gave LAND a "Neutral" grade with a "hold" action.
Gladstone Land Corporation holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Gladstone Land Corporation:
Founded in 1997, Gladstone Land is a publicly traded real estate investment trust that acquires and owns farmland and farm-related properties located in major agricultural markets in the U.S. and leases its properties to unrelated third-party farmers. The Company, which reports the aggregate fair value of its farmland holdings on a quarterly basis, currently owns 127 farms, comprised of approximately 94,000 acres in 13 different states, valued at approximately $1.0 billion. Gladstone Land's farms are predominantly located in regions where its tenants are able to grow fresh produce annual row crops, such as berries and vegetables, which are generally planted and harvested annually. The Company also owns farms growing permanent crops, such as almonds, apples, figs, olives, pistachios, and other orchards, as well as blueberry groves and vineyards, which are generally planted every 10 to 20-plus years and harvested annually. The Company may also acquire property related to farming, such as cooling facilities, processing buildings, packaging facilities, and distribution centers. The Company pays monthly distributions to its stockholders and has paid 93 consecutive monthly cash distributions on its common stock since its initial public offering in January 2013. The Company has increased its common distributions 20 times over the prior 23 quarters, and the current per-share distribution on its common stock is $0.0449 per month, or $0.5388 per year.
The Paypay Corporation stock price fell by -5.01% on the last day (Friday, 10th Apr 2026) from $21.16 to $20.10. During the last trading day the stock fluctuated 5.28% from a day low at $20.06 to a day high of $21.12. The price has been going up and down for this period, and there has been a -11.49% loss for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -371 thousand shares and in total, 689 thousand shares were bought and sold for approximately $13.84 million.
Paypay Corporation holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
The Biogen Inc. stock price fell by -2.34% on the last day (Friday, 10th Apr 2026) from $177.11 to $172.97. During the last trading day the stock fluctuated 3.28% from a day low at $172.32 to a day high of $177.97. The price has fallen in 6 of the last 10 days and is down by -9.47% for this period. Volume has increased on the last day by 60 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 1 million shares were bought and sold for approximately $229.39 million.
On May 27, 2026, it was reported that RBC Capital gave BIIB a "Outperform" grade with a "hold" action.
Biogen Inc. holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Biogen Inc.:
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
The AnaptysBio Inc stock price gained 2.28% on the last trading day (Friday, 10th Apr 2026), rising from $45.69 to $46.73. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 4.92% from a day low at $44.55 to a day high of $46.74. The price has risen in 7 of the last 10 days and is up by 7.86% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 131 thousand more shares were traded than the day before. In total, 690 thousand shares were bought and sold for approximately $32.26 million.
On May 13, 2026, it was reported that UBS gave ANAB a "Buy" grade with a "hold" action.
AnaptysBio Inc holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About AnaptysBio Inc:
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
RUN
$12.83
|
4.09% | May 06 |
GLBE
$31.61
|
1.65% | May 05 |
SAP
$172.39
|
7.18% | May 05 |
FIZZ
$34.11
|
7.04% | May 01 |
ADBE
$243.57
|
3.23% | Apr 29 |
